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A B S T R A C T
Background: In a pivotal, phase 2b study (NCT01854047) in patients with uncontrolled persistent asthma,
despite using medium-to-high-dose inhaled corticosteroids plus long-acting b2 agonists, dupilumab improved
lung function, reduced severe exacerbations, and showed an acceptable safety profile.
Objective: To assess the impact of dupilumab on asthma control, symptoms, quality of life (QoL), and productivity.
Methods: Data are shown for the intention-to-treat population receiving dupilumab 200/300 mg every 2 weeks
(doses being assessed in phase 3; NCT02414854), or placebo. Predefined analyses of total scores were conducted
at week 24 for the 5-item Asthma Control Questionnaire (ACQ-5), patient-reported morning/evening (AM/PM)
asthma symptoms, Asthma Quality of Life Questionnaire (AQLQ), and asthma-related productivity loss.
Responder rate analyses for these measures, subgroup analyses by baseline characteristics, and asthma-related
productivity loss analyses were conducted post hoc.
Results: Data from 465 patients were analyzed (158 placebo; 307 dupilumab). Both dupilumab doses signifi-
cantly improved scores through week 24 (all outcomes, overall population). The proportion of patients meeting
or exceeding the minimal clinically important difference for the overall population were significantly greater vs
placebo (P < .05) for ACQ-5 (range, 72.6%-76.7% vs 61.4%), for AM/PM asthma symptoms score (48.7%-54.1% vs
34.2% and 52.7%-53.5% vs 34.2%, respectively) and for AQLQ (64.0%-65.0% vs 51.3%). The effect of dupilumab was
consistent across most subgroups. Productivity loss was significantly higher in placebo- vs dupilumab-treated
patients (P < .0001).
Conclusion: Dupilumab produced significant, clinically meaningful improvements in asthma control, symptoms,
QoL, and productivity.
Registration: ClinicalTrials.gov Identifier: NCT01854047.
© 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Introduction
Asthma is a heterogeneous disease consisting of phenotypes
defined, in part, by clinical parameters such as age of onset, presence
of allergic features, degree of airway obstruction, obesity, sex, and
smoking history.1-3 These characteristics may be associated with out-
come and treatment response.3 Poor asthma control has been associ-
ated with increased risk of asthma exacerbations, asthma-related
hospitalization,4,5 poor quality of life (QoL),6 adverse impact on pro-
ductivity,7,8 and possibly, increased risk of mortality.9-11
Dupilumab, a fully human monoclonal antibody directed against
the interleukin (IL)-4 receptor-a, inhibits signaling of IL-4 and IL-13.
These cytokines are key drivers of type 2/Th2 immune responses that
occur in asthma, allergic rhinitis, food allergies, and atopic dermatitis
(AD). Dupilumab is approved in the European Union, United States,
and other countries for the treatment of adults with inadequately
controlled moderate-to-severe AD. Dupilumab is under clinical devel-
opment for the treatment of uncontrolled persistent asthma, chronic
rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
A pivotal, phase 2b, dose-ranging study (ClinicalTrials.gov Identi-
fier: NCT01854047) assessed the efficacy and safety of dupilumab in
patients with uncontrolled persistent asthma despite the use of
medium-to-high-dose inhaled corticosteroids (ICS) plus a long-acting
b2-agonist (LABA).12 Dupilumab significantly reduced severe asthma
exacerbation rates and improved pulmonary function in both the over-
all study population and in subgroups defined by baseline eosinophil
count (<300 and ≥300 cells/mL), while also demonstrating an accept-
able safety profile.12 When assessed using standard patient-reported
outcome (PRO) questionnaires at baseline, more than half of the
patients in the study had at least a moderate degree of impaired physi-
cal or emotional functioning.13 Secondary outcomes that measured
asthma control, asthma symptoms, and disease-specific health-related
QoL showed that patients receiving dupilumab had improvements in
each of these outcomes, irrespective of baseline eosinophil count.12
Although the main goals of asthma treatment include reduction of
symptoms, improvement in QoL, and prevention of exacerbations, clini-
cal trials of new treatments have primarily focused on exacerbations
and lung function as key endpoints. PROs such as symptom control and
QoL are increasingly being recognized as being important in asthma,
and regulatory agencies often request inclusion of these outcomes in
clinical trials.14-16 Furthermore, treatment effects on exacerbations, lung
function, and PROs show only modest correlations, making each mea-
sure a useful independent assessment.
In this post hoc analysis of the phase 2b study, we aimed to further
investigate the effect of dupilumab on PROs by examining individual
patient response rates and consistency of effect in specific patient
subgroups, defined by baseline characteristics. In addition, we exam-
ined whether dupilumab treatment could affect loss of productivity
in the workplace attributable to asthma.
Methods
Study design, inclusion and exclusion criteria, and main efficacy
and safety outcomes of this randomized, double-blind, placebo-con-
trolled, parallel-group, multicenter, multinational, pivotal, phase 2b
clinical trial have been described previously.12 Main inclusion criteria
were: adults; asthma diagnosis17 for 12 months or longer; treatment
with medium-to-high-dose ICS+LABA with a stable dose of ICS+LABA
for 1 month or longer before screening; pre-bronchodilator forced
expiratory volume in 1 second (FEV1) 40% to 80% of predicted, with
reversibility of at least 12% and at least 200 mL in FEV1 after 200 to
400 mg salbutamol at screening; 5-item Asthma Control Question-
naire (ACQ-5) total score18 1.5 or higher at screening and study base-
line; and 1 or more systemic corticosteroid burst therapy, hospital
admission, or an emergency or urgent medical care visit that required
treatment with systemic steroids for worsening asthma within 1 year
before screening. Main exclusion criteria were diagnosis of chronic
obstructive pulmonary disease or other lung disease impairing pul-
monary function; b-adrenergic receptor blocker use; use of systemic
corticosteroids within 28 days of, or during, the screening period;
current smoker, more than 10 pack-years smoking history, or cessa-
tion of smoking within 6 months of screening.
Patients were randomized (1:1:1:1:1) by a centralized treatment
allocation system to receive placebo or 1 of the doses of subcutaneous
dupilumab (200 mg or 300 mg) every 2 weeks (q2w) or every 4 weeks
(q4w) for 24 weeks, followed by a 16-week follow-up period. Because
only the 200mg and 300mg every 2 weeks regimens were further eval-
uated in phase 3 clinical trials, this manuscript reports the findings with
these doses. This study was done in accordance with the principles
established in the Declaration of Helsinki and the International Confer-
ence on Harmonisation guidelines for Good Clinical Practice. All study
documents and procedures were approved by the appropriate institu-
tional review board or ethics committee at each study site (e-Appendix
1). All patients provided written informed consent before participation
in the study.12
Asthma control was assessed as change from baseline to week 24 in
ACQ-5 total score and individual items (frequency of waking during the
night, asthma morning symptoms, activity limitation, shortness of
breath, and wheezing caused by asthma).18,19 The ACQ-5 scores range
from 0 (excellent asthma control) to 6 (poor asthma control).
Asthma symptoms were assessed as change from baseline to week
24 in asthma symptom scores (range, 0-4), using daily patient self-
reported morning (AM) and evening (PM) asthma symptoms
recorded using an electronic diary. The AM asthma symptom score is
a 1-item question recorded on rising and assesses asthma symptoms
occurring at night (0 = no asthma symptoms, slept through night;
4 = bad night, awake most of night because of asthma). The PM
asthma symptom score is a 1-item question recorded in the evening,
and it assesses asthma symptoms that occurred during the day
(0 = very well, no asthma symptoms; 4 = asthma very bad, unable to
carry out daily activities as usual). Baseline AM or PM scores are the
average of the respective scores recorded for 7 days.
Quality of life was assessed as change from baseline to week 24 in
the Asthma Quality of Life Questionnaire (AQLQ), a 32-item question-
naire composed of 4 health-related QoL domains (activity limitation,
emotional function, exposure to environmental stimuli, and asthma
symptoms) rated on a 7-point Likert-like scale (1 = totally limited, all
the time, a very great deal, or severely limited; 7 = not at all limited,
none, or no discomfort/distress).20
Productivity loss was measured using a patient-reported health care
resource utilization questionnaire that included an assessment of the
number of days lost from work, whether a patient experienced at least
1 day of sick leave from work because of a severe exacerbation event
during the 24-week treatment period, and calculated the annualized
rate of sick leave caused by severe exacerbation events. A severe exacer-
bation event was defined as the deterioration of asthma requiring use of
systemic corticosteroids for at least 3 days or hospitalization or emer-
gency room visit because of asthma requiring systemic corticosteroids.
To further explore the effects of dupilumab, analyses were also per-
formed on subgroups of patients with baseline clinical characteristics
associated with different asthma phenotypes. Subgroups included:
sex, body mass index, age at asthma onset, FEV1, FEV1 percentage pre-
dicted, postbronchodilator reversibility, number of severe asthma
exacerbations in the year before the study, ICS+LABA dose at randomi-
zation, eosinophil count, history of atopy (defined as 2 or more positive
aeroallergen-specific IgE antibodies at baseline), and smoking history.
Results are reported for all patients randomized to receive placebo
dupilumab 200 mg every 2 weeks or 300 mg every 2 weeks (ie, the
dupilumab regimens under investigation in phase 3 [ClinicalTrials.
gov Identifier: NCT02414854]). Changes from baseline at week 24 for
ACQ-5, AM and PM asthma symptom scores, and AQLQ total scores
for the intention-to-treat overall population, and by eosinophil count
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less than 300 and at least 300 cells/mL were predefined endpoints in
the original study.12 Post hoc analyses included responder rates at
week 24 for ACQ-5, AM/PM asthma symptom scores, AQLQ, and
changes from baseline at week 24 for the individual items or domains
of the ACQ-5 and AQLQ scores, subgroups, and productivity.
A mixed-effect model with repeated measures was used with
changes from baseline scores to week 24 as dependent variables.
Factors (fixed effects) for treatment, pooled countries/regions, visit,
treatment-by-visit interaction, baseline eosinophil strata, baseline
scores, and baseline-by-visit interaction were covariates, with an
unstructured correlation matrix. The interactions were obtained
using a mixed-effect model with repeated measures with additional
terms for the subgroup under consideration, treatment-by-subgroup
interaction, and subgroup-by-treatment-by-visit interaction.
Responder rates were defined as the proportions of patients with
scores exceeding the threshold of the minimum clinically important dif-
ference (MCID). To aid clinical interpretability of the PRO findings, two
MCIDs are presented for each questionnaire. The first analysis used an
MCID of 0.5 for ACQ-5 and AQLQ21,22 and 0.35 for AM/PM asthma symp-
tom score. The ACQ-5 and AQLQ thresholds are based on published liter-
ature. The AM/PM MCID was derived using Cohen’s rule (ie, scores
beyond half the standard deviation [SD] are considered clinically mean-
ingful). The second analysis used more conservative MCID estimates;
selected MCIDs were 0.6 for ACQ and AQLQ and 0.4 for AM/PM symp-
toms. Responder rates were compared between treatment groups using
multiple logistic regression models for each specific patient subgroup,
with response status as the dependent variable and treatment, pooled
countries/regions, and baseline score value as covariates.
Table 1
Baseline Characteristics (ITT Population)
Dupilumab
Placebo (n = 158) 200 mg every 2 weeks (n = 150) 300 mg every 2 weeks (n = 157)
Demographic characteristics
Mean age, years (SD) 49.0 (12.7) 51.0 (13.4) 47.5 (12.4)
Male sex, n (%) 54 (34.2) 54 (36.0) 54 (34.4)
Race, n (%)
White 119 (75.3) 114 (76.0) 129 (82.2)
Black or African American 9 (5.7) 9 (6.0) 5 (3.2)
Asian 25 (15.8) 25 (16.7) 22 (14.0)
Other 5 (3.2) 2 (1.3) 1 (0.6)
Employment status at baseline
Full-time, n (%) 79 (52.3) 65 (45.8) 69 (46.9)
Part-time, n (%) 14 (9.3) 16 (11.3) 18 (12.2)
Unemployed, n (%) 46 (30.5) 43 (30.3) 47 (32.0)
Retired, n (%) 12 (7.9) 18 (12.7) 13 (8.8)
Missing, n 7 8 10
Clinical characteristics
BMI ≥ 30 kg/m2, n (%) 60 (38.0) 65 (43.3) 63 (40.1)
Mean baseline eosinophils/mL (SD) 342.3 (300.0) 361.1 (352.7) 322.9 (245.1)
Time since first asthma diagnosis
Number 158 149 156
Mean, years (SD) 21.96 (16.46) 23.95 (15.73) 20.21 (13.43)
Mean FEV1, L (SD) 1.82 (0.55) 1.79 (0.52) 1.85 (0.53)
Mean FEV1, % predicted (SD) 60.96 (10.72) 61.23 (11.00) 60.76 (10.39)
Number of asthma exacerbations in past year
Number of patients 158 150 157
Mean (SD) 2.27 (2.25) 1.85 (1.43) 2.37 (2.29)
High-dose ICS+LABA usea
Patients, n 155 144 153
n (%) 77 (49.7) 75 (52.1) 79 (51.6)
Any type 2 related comorbidity,b n (%) 108 (70.1) 106 (71.1) 104 (67.5)
Atopic dermatitis 16 (10.4) 10 (6.7) 16 (10.4)
Allergic rhinitis 102 (66.2) 99 (66.4) 94 (61.0)
Chronic rhinosinusitisc 18 (11.7) 23 (15.4) 32 (20.8)
Nasal polyposis 18 (11.7) 25 (16.8) 30 (19.5)
Food allergy 17 (11.0) 18 (12.1) 13 (8.4)
PROs
ACQ-5 total score (0 to 6, where 6 is worst)
Patients, n 158 150 157
Mean (SD) 2.69 (0.80) 2.73 (0.82) 2.80 (0.83)
AQLQ total score (1 to 7, where 1 is worst)
Patients, n 156 148 153
Mean (SD) 4.12 (1.10) 4.03 (1.15) 3.91 (1.13)
Mean AM/PM symptom score (0 to 4, where 4 is worst)
AM score (SD) 1.17 (0.79) 1.24 (0.81) 1.25 (0.78)
PM score (SD) 1.32 (0.81) 1.42 (0.79) 1.47 (0.85)
Smoking history
Patients, n 158 150 157
Former smoker, n (%) 34 (21.5) 32 (21.3) 36 (22.9)
Pack-year
Patients, n 34 32 35
Mean (SD) 4.31 (3.13) 4.33 (3.15) 3.88 (3.42)
Abbreviations: ACQ-5, 5-item Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; FEV1, forced expiratory volume (L) in 1 second;
ICS, inhaled corticosteroids; ITT , intention to treat; LABA, long-acting b2-agonist; PRO, patient-reported outcome; SD, standard deviation.
aUse of ICS+LABA was recorded in an electronic diary.
bAssessed by clinical history.
cChronic rhinosinusitis included patients with and without nasal polyposis.
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Figure 1. Effect of dupilumab at week 24 on: A: ACQ-5 total score and individual items; B: AM/PM asthma symptom score; and C: AQLQ total score and related domains. ACQ-5, 5-
item Asthma Control Questionnaire; AM/PM, patient-reported morning/evening asthma symptoms; AQLQ, Asthma Quality of Life Questionnaire; CI, confidence interval; LS, least
squares; q2w, every 2 weeks; SE, standard error.
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Unadjusted rates for productivity loss were derived using total
number of days of sick leave during the treatment period (between first
dose date and last dose date +14 days) divided by total number of
patient-years followed in the treatment period. P values were estimated
using adjusted analyses; Poisson model with the total number of events
onset between first dose date and last dose date +14 days as the
response variable; treatment, pooled countries/regions, and number of
asthma events prior to the study as covariates; and log-transformed
standardized treatment duration as an offset variable.
No type I error adjustments for multiplicity were applied in
reporting the results. P ≤ .05 were considered statistically significant.
Results
Baseline Disease Burden
Seven hundred seventy-six patients were enrolled in the phase 2b
trial; this analysis, which examines both predefined and post hoc
endpoints, included 465 patients randomized to either the placebo
group (n = 158), or to the dupilumab group (200 mg every 2 weeks or
300 mg every 2 weeks; n = 307). Overall, demographics, clinical char-
acteristics, and PRO scores were generally similar across the treat-
ment groups at baseline (Table 1).
PROs
At week 24, both dupilumab regimens (200 and 300 mg every 2
weeks) resulted in significant improvements in ACQ-5 total score (least
squares mean difference vs placebo ¡0.35 and ¡0.31, respectively;
Fig 1A, eFig 1), AM asthma symptom score (¡0.22 and ¡0.20; Fig 1B,
eFig 2), PM asthma symptom score (¡0.21 and¡0.23; Fig 1B, eFig 3), and
AQLQ total score (0.32 and 0.36; Fig 1C, eFig 4) (all P< .01).
Dupilumab 200 mg every 2 weeks significantly improved
each individual item of the ACQ-5 vs placebo, whereas dupilumab
300 mg every 2 weeks significantly improved 3 of the 5 items
(Fig 1A). With the exception of “environmental stimuli,” both doses
Table 2
Proportions of Responders at Week 24a
Dupilumab
Placebo (n = 158) 200 mg q2w (n = 150) 300 mg q2w (n = 157)
Proportion of patients meeting or exceeding the MCIDb ACQ-5 total score 61.4 76.7e 72.6d
AM asthma symptom score 34.2 48.7d 54.1e
PM asthma symptom score 34.2 52.7e 53.5e
AQLQ total score 51.3 64.0d 65.0d
Proportion of patients meeting or exceeding the MCIDc ACQ-5 total score 60.1 76.7e 72.6d
AM asthma symptom score 31.0 46.7e 51.0e
PM asthma symptom score 31.0 50.0e 51.6e
AQLQ total score 47.5 60.7d 63.1e
Abbreviations: ACQ-5, 5-item Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; MCID, minimal clinically important difference; q2w, every 2 weeks.
aPatients whomet the corresponding criterion are considered as responders. Patients who did notmeet the criterion or hadmissing value are considered as non-responders. P-values are
derived from a logistic regressionmodel with treatment, region (Asia, Latin America, East Europe, orWestern Countries), baseline eosinophil stratum, and baseline score as covariates.
bFor this analysis, MCIDs are 0.5 for ACQ-5 and AQLQ, and 0.35 for AM/PM asthma symptom scores.
cFor this analysis, MCIDs are 0.6 for ACQ-5 and AQLQ, and 0.40 for AM/PM asthma symptom scores.
dP < 0.05 vs placebo.
eP ≤ 0.01 vs placebo.
Figure 1. Continued.
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of dupilumab significantly improved all AQLQ domains compared
with placebo (Fig 1C).
PRO MCID Analysis
LS mean change from baseline was higher than the MCID for all
treatment cohorts on the ACQ-5 total score, AM and PM asthma
symptom score, and total AQLQ overall score (Fig 1). The proportion
of patients meeting or exceeding the respective MCIDs for each of the
PROs assessed are shown in Table 2. Responder rates were greater for
dupilumab-treated patients compared to placebo on the ACQ-5, the
AM and PM asthma symptom scores and the AQLQ (P < .05 for the
200 mg q2w and 300 mg q2w dose vs placebo for all tests).
Productivity Loss
Employment status at baseline (either full- or part-time) was
comparable across treatment groups (Table 1). Assessment of produc-
tivity loss related to severe exacerbation events revealed a total of 22
and 24 days of sick leave in the dupilumab 200 and 300 mg every
2 weeks groups, respectively, compared with 92 days with placebo (P<
.001). These translate to unadjusted annualized rates of sick leave
because of severe exacerbations of 0.6 days per patient receiving either
dose of dupilumab regimen vs 2.2 days for placebo-treated patients
(P< .0001 for either dupilumab dose; Table 3), which amounts to a 73%
and 72% reduction in loss of productivity for the dupilumab 200 and
300 mg every 2 weeks regimens vs placebo, respectively.
Table 3
Effect of Dupilumab on Productivity Loss
Dupilumab
Placebo (n = 158) 200 mg every 2 weeks (n = 150) 300 mg every 2 weeks (n = 157)
Total number of severe exacerbation events 75 20 23
Total number of patients employed ITT 93 (58.9%) 81 (54.0%) 87 (55.4%)
Number of employed patients with ≥1 day of sick leave
(work) due to severe exacerbation event
Yes 11 (11.8%) 4 (4.9%) 5 (5.7%)
No 82 (88.2%) 77 (95.1%) 82 (94.3%)
Total days of sick leave (work) due to severe exacerbation
event
92 22 24
Total days of sick leave (work) due to severe exacerbation
event/per severe exacerbations
1.23 1.10 1.04
Total patient-years followed 41.1 35.9 38.9
Unadjusted annualized days of sick leave due to severe
exacerbation event (days/year)a
2.238 0.613b 0.617b
Abbreviation: ITT, intention to treat.
aThe total number of events during the treatment period (between first dose date and last dose date + 14 days) divided by the total number of patient-years followed in the treat-
ment period.
bP < .0001 with adjusted analyses; Poisson model with the total number of events onset between first dose date and last dose date + 14 days as the response variable, treatment,
pooled countries/regions, and number of asthma events because of the study as covariates, and log-transformed standardized (in years) treatment duration as an offset variable.
Figure 2. ACQ-5, analysis by baseline covariates. A: ACQ-5 analysis by baseline covariates, Week 24 200 mg every 2 weeks; B: ACQ-5 analysis by baseline covariates, Week 24
300 mg every 2 weeks. ACQ-5, 5-item Asthma Control Questionnaire; BMI, body mass index; FEV1, forced expiratory volume (L) in 1 second; ICS; inhaled corticosteroids; LABA,
long-acting b2-agonist; q2w, every 2 weeks; SE, standard error.
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PROs in Patient Subgroups
The effect of dupilumab on ACQ-5 total score, AM/PM
asthma symptom scores, and AQLQ total score for each of the sub-
groups examined is shown in Figures 2 through 5. Significant
improvements from baseline to week 24 were observed in many of
the subgroups for both dupilumab regimens compared with placebo.
Significant treatment-by-subgroup interactions were seen for the
following baseline characteristics: sex, number of exacerbations in
the previous year, FEV1, eosinophil count, and postbronchodilator
reversibility (Fig. 2-5). The magnitude of the treatment effect varied
by subgroup but was consistently favored by dupilumab treatment.
ICS/LABA dose level at randomization, history of atopy, and smoking
history had nonsignificant treatment-by-subgroup interactions for
Figure 3. Morning asthma symptom scores, analysis by baseline covariates. A: Morning asthma symptom scores, Week 24 200 mg every 2 weeks; B: Morning asthma symptom
scores, week 24 300 mg every 2 weeks.
Figure 4. Evening asthma symptom scores, analysis by baseline covariates. A: Evening asthma symptom scores, week 24 200 mg every 2 weeks; B: Evening asthma symptom
scores, week 24 300 mg every 2 weeks.
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ACQ-5, AQLQ, and AM/PM asthma symptom scores. Patients with
baseline characteristics usually associated with more severe asthma,
including history of more than 1 exacerbation in the prior year or
baseline FEV1 of at least 1.75L, showed a better response to both dupi-
lumab regimens vs placebo in ACQ-5, AM/PM asthma symptom
scores, and AQLQ score (P < .05 for all) (Fig. 2-5).
Safety
As reported in detail in the primary manuscript, rates of treat-
ment-emergent adverse events were similar across treatment groups,
as were rates of serious treatment-emergent adverse events.12 Injec-
tion-site reactions occurred more often in active treatment groups,
and they were dose-related (20% and 26% for dupilumab 200 and
300 mg every 2 weeks, respectively, vs 13% for placebo).12
Discussion
Despite receiving medium-to-high-dose ICS+LABA therapy,
patients with uncontrolled persistent asthma are characterized by a
multidimensional burden of disease, including recurrent exacerba-
tions, reduced lung function, and reduced QoL. In addition, patients
with uncontrolled persistent asthma often suffer from other allergic
comorbidities such as chronic sinusitis and AD, further complicating
the treatment of these patients.
In this pivotal phase 2b trial, dupilumab every 2 weeks dose regi-
mens significantly improved lung function, severe exacerbation rates,
and patient-centered outcomes (asthma symptoms, asthma control,
and QoL) relative to placebo when added to medium-to-high-dose
ICS+LABA therapy in adults with uncontrolled persistent asthma.12
Significant improvements in all of these endpoints were observed in
both the overall population and patients with eosinophil counts of at
least 300 cells/mL. Lung function and exacerbation rates were also
significantly improved in patients with eosinophil counts less than
300 cells/mL.12
In this post hoc analysis, we demonstrated that dupilumab signifi-
cantly improved asthma control, asthma symptoms, QoL, and work-
place productivity in the overall population, as well as in a majority
of subgroups evaluated; results from the MCID analysis showed that
the improvements were clinically meaningful, and consistent with
analysis of previously reported mean changes in PROs, where a
greater proportion of dupilumab-treated patients benefited from
treatment compared to placebo.
Of particular note, significant improvements were observed in
patients with a history of more than 1 exacerbation at baseline, or
FEV1 of at least 1.75 L (both dupilumab every 2 weeks dose regimens)
at baseline, but not patients with 1 exacerbation or baseline FEV1
greater than 1.75 L. Although a consistent significant improvement
was observed with baseline eosinophil count of at least 300 cells/mL
for dupilumab vs placebo, patients with less than 300 cells/mL only
observed an improvement in ACQ-5 with 200mg every 2 weeks dupi-
lumab vs placebo. These observations suggest that dupilumab may
have a greater effect on PROs in patients with more severe asthma
and a higher type 2 inflammatory signal at baseline.
Additionally, despite the small sample size (which is an important
limitation of this analysis), a significant improvement was observed
with dupilumab (200 and 300 mg every 2 weeks) on patient-reported
AM asthma symptoms in patient subgroups with eosinophils of at
least 300 cells/mL and less than 300 cells/mL; this is a unique finding
compared with those of other studies investigating the use of anti-IL-
5 in this patient population. These data are consistent with the overall
benefit of dupilumab observed in patients with eosinophils at least
300 cells/mL and less than 300 cells/mL.12 Because of the small num-
ber of patients with less than 150 eosinophils/mL (n = 30 on the 200
mg every 2 weeks and n = 28 on the 300mg every 2 weeks dupilumab
arms), these data were not presented, because no meaningful com-
parisons could be drawn between the dupilumab and placebo groups.
Larger, ongoing phase 3 studies will be needed to confirm these pre-
liminary findings.
Another important finding from this post-hoc analysis is the effect
of dupilumab on work productivity improvement. To our knowledge,
Figure 5. AQLQ, analysis by baseline covariates. A: AQLQ analysis by baseline covariates, week 24 200 mg every 2 weeks; B: AQLQ analysis by baseline covariates, week 24 300 mg
every 2 weeks. ACQ-5, 5-item Asthma Control Questionnaire; BMI, body mass index; FEV1, forced expiratory volume (L) in 1 second; ICS; inhaled corticosteroids; LABA, long-acting
b2-agonist; q2w, every 2 weeks; SE, standard error.
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this is the only double-blind, randomized controlled trial that demon-
strates the effects of a biologic (dupilumab) on workplace productiv-
ity in patients with uncontrolled persistent asthma. Furthermore, no
evidence has been seen of significant improvement in productivity in
patients with uncontrolled persistent asthma treated with biologics
targeting IL-5.23
In conclusion, patients with uncontrolled persistent asthma who
do not respond to currently available therapies are in need of addi-
tional treatment options. This analysis demonstrates that dupilumab
every 2 weeks regimens provide significant and clinically meaningful
improvements in asthma control, asthma symptoms, and QoL and
significantly improve workplace productivity. Furthermore, improve-
ments in these PROs were observed across a range of asthma pheno-
types determined by baseline clinical characteristics.
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eFigure 2. Change from baseline in AQLQ over time in the overall population.
eFigure 3. Change from baseline in morning asthma symptom scores over time in the overall population.
eFigure 1. Change from baseline in ACQ-5 over time in the overall population.
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eFigure 4. Change from baseline in evening asthma symptom scores over time in the overall population.
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